Table 3

Clinical, angiographic, outcome and follow-up data of embolized cases

	Clinical features	Imaging	Type	Jugular vein status	Outcome	Follow-up*
Neonates
1	FD	PAH	Choroidal	Patent	Improved	7
2	CHF	CD	Mural	Patent	Improved	8
3	CHF	CD	Choroidal	Patent	Died	1 day
4	CHF	H, WM	Mural	Patent	Died	8 days
5	FD	MB	Choroidal	Atresia	Died	2 days
Infants
6	CHF	H	Mural	Patent	Improved	120
7	MC, DD	H	Mural	Patent	Improved	24
8	MC	H, AT	Mural	Stenosis	Improved	36
9	MC, DD, Sz	H, AT, SC	Mural	Stenosis	Deteriorated	84
10	MC, Sz	H	Mural	Stenosis	Improved	12
11	DD, Sz	H, WM	Mural	Atresia	Deteriorated	18
12	DD, Sz	H, BC	Choroidal	Atresia	Deteriorated	7
13	MC	H	Choroidal	Patent	Stable	6
14	MC, DD	H, AT	Mural	Patent	Improved	6
15	MC, DD, Sz	H, SC, WM	Choroidal	Atresia	Deteriorated	6
16	MC, DD, Sz	H, AT, WM	Choroidal	Atresia	Deteriorated	12
Children
17	HA, V	H, IVH	Choroidal	Patent	Improved	6
18	Sz, DD	H, AT	Mural	Patent	Improved	9
19	HA, V, VL	H	Choroidal	Stenosis	Improved	18
20	E, P, FV	H	Mural	Stenosis	Improved	6
21	Sz, P, FV	H	Mural	Patent	Improved	6
Adults
22	HA, FV	H, BC	Mural	Stenosis	Improved	192
23	HA	H	Choroidal	Patent	Died	2 days

*Follow-up is given in months unless specified otherwise.
AT, cerebral atrophy; BC, basal ganglia calcification; CD, cardiomegaly; CHF, congestive heart failure; DD, developmental delay; E, epistaxis; FD, feeding difficulty; FV, prominent facial veins; H, hydrocephalus; HA, headache; MB, melting brain; MC, macrocrania; P, proptosis; PAH, pulmonary arterial hypertension; SC, subcortical calcification; Sz, seizure; V, vomiting; VL, visual loss; WM, cerebral white matter signal change.